Novo Nordisk was a pioneer in developing ... validation through two FDA-approved Ascendis products. Skytrofa, a drug for pediatric growth hormone deficiency, won its FDA nod in 2021.

Novo Nordisk (NVO), the maker of blockbuster weight-loss and diabetes drugs Wegovy and Ozempic, has entered an agreement with Denmark-based Ascendis Pharma (ASND) to leverage the latter’s advanced ...

Novo Nordisk A/S (NYSE:NVO) is expanding into areas such as cardiovascular disease and focusing on products for hemophilia, growth disorders, and hormone replacement therapies. Novo Nordisk A/S ...

We recently compiled a list of the 8 Best European Stocks To Buy According to Hedge Funds. In this article, we are going to ...

Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.

The collaboration will focus on Novo Nordisk’s obesity and type 2 diabetes products, chief among them ... to treat growth hormone deficiency. Ascendis stock saw a slight uptick following the ...

Occasionally, a breakthrough comes along that fundamentally transforms the medical landscape, to the extent that it is difficult to imagine what life was like before it emerged. - In 1928, it was ...

It has the ring of a Hans Christian Andersen fairytale—if a supremely ironic one. Tiny Denmark is home to six million of the world's wealthiest and healthiest people—all those muesli-munching ...

Novo Nordisk and Ascendis Pharma have agreed to collaborate in developing metabolic and cardiovascular therapies, among them ...